How many weeks should a full PCT run after a Cut Mix 300 cycle using short esters?

A standard post-cycle therapy following a short-ester blend like Cut Mix 300 typically runs 4–6 weeks. Because propionate and acetate esters clear within 3–5 days of the last injection, hormonal recovery can begin earlier than with long-ester cycles. Most protocols use a SERM (Nolvadex or Clomid) for 4 weeks minimum, extending to 6 weeks if suppression was deep or cycle duration exceeded 10 weeks.

Can running PCT for too long after a tri-ester cutting cycle cause any harm?

Prolonged SERM use beyond 6–8 weeks can itself disrupt oestrogen signalling, potentially affecting lipid profiles and joint lubrication. There is no therapeutic benefit to extending SERM administration once bloodwork confirms LH, FSH, and testosterone have normalised. Monitoring via blood panels at weeks 4 and 6 of PCT is the standard method for determining when to stop rather than defaulting to a fixed extended duration.

When can PCT be shortened after Cut Mix 300, and what conditions allow it?

PCT can potentially be shortened to 3–4 weeks when cycle duration was brief (6–8 weeks), suppression was moderate rather than severe, and blood panels at the end of week 3 already show LH and testosterone returning toward baseline. Short-ester clearance via propionate and acetate de-esterification means recovery hormones are unobstructed earlier, but bloodwork confirmation — not assumptions — should determine when PCT can be concluded.

Can Cut Mix 300 be drawn into an insulin syringe for small-dose injections?

Insulin syringes (0.5ml or 1ml, 27–29 gauge) can technically draw Cut Mix 300, but the 300mg/ml concentration means even a 0.25ml draw delivers 75mg of combined actives — making micro-precision essential. The narrow gauge slows draw time with viscous oil; warming the vial to body temperature (38–40°C) in a warm-water bath for 2–3 minutes reduces viscosity and eases insulin-syringe loading without degrading the active compounds.

How should the Cut Mix 300 10ml vial be stored after first use?

After the rubber stopper is first punctured, store the vial in a cool, dark environment between 15–25°C — room temperature is acceptable for multi-dose vials sealed with chlorobutyl stoppers. Refrigeration (2–8°C) extends shelf life but may cause the oil solution to thicken; allow the vial to return to room temperature before drawing. Avoid repeated temperature cycling. Discard any vial showing visible particulate matter, cloudiness, or colour change regardless of remaining volume. (2) angle_used

Strength Booster

Military Pharma

Cut Mix 300 300mg/ml 10ml Vial by Military Pharma

Name: Cut Mix 300 300mg/ml 10ml Vial by Military Pharma
Brand: Military Pharma
SKU: INJ-MIX-MIL-300-007
Price: 59.00 EUR
Availability: InStock

Cut Mix 300 by Military Pharma delivers Testosterone Propionate 100mg/ml, Trenbolone Acetate 100mg/ml, and Drostanolone Propionate 100mg/ml in a single 300mg/ml injectable formulation — engineered for experienced athletes who apply deliberate site-rotation discipline to manage localised discomfort at elevated concentration. Each 1ml draw contains 300mg of combined short-ester actives, halving the injection volume required versus a 150mg/ml equivalent while placing a higher per-site chemical load that demands structured protocol management. Every 10ml vial batch undergoes HPLC quantification of each active fraction alongside LAL endotoxin screening prior to distribution clearance.

€59.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Delivers 300mg of combined cutting agents per millilitre — halving injection volume versus 150mg/ml alternatives at equivalent weekly dosing.
Three complementary short esters create overlapping anabolic and androgenic coverage without long clearance windows.
Drostanolone Propionate's DHT-derived hardening effect pairs directly with Testosterone Propionate's anabolic base in each injection.
Trenbolone Acetate's nitrogen retention and nutrient partitioning properties support lean mass preservation throughout a caloric deficit.
Short-ester composition enables PCT to begin within 3–5 days of the last injection, compressing total cycle-to-recovery time.
10ml multi-dose vial yields 3,000mg total active ingredients — sufficient for a structured multi-week cutting phase from a single unit.
Tactically optimised carrier oil formulation targets crystallisation resistance at high concentration, reducing a secondary PIP risk factor.

Phase	dosage	Note
Introductory Phase (Week 1–2)	0.5ml every other day (150mg total actives per injection)	Assess individual PIP response at 300mg/ml before committing to full dose; rotate between two sites minimum.
Full Protocol Phase (Week 3–8)	1ml every other day (300mg total actives per injection)	Maintain a strict 4-site rotation (bilateral glutes + bilateral quads or deltoids); allow 7-day rest per site.
PIP-Sensitive Adjustment	0.75ml every other day (225mg total actives per injection)	If site inflammation accumulates, reducing volume per injection while increasing frequency maintains weekly totals with lower per-site load.
Final Week (Week 8–10 depending on protocol)	Taper to 0.5ml every other day	Tapered exit reduces depot load before PCT; short esters clear within 3–5 days enabling fast SERM initiation.

Key takeaways

Rotate injection sites every 7 days minimum to prevent cumulative PIP buildup.
Warm the vial before drawing to reduce viscosity and injection discomfort.
Start PCT 3–5 days post-final injection — short esters clear rapidly.
Expect higher PIP frequency at 300mg/ml compared to 150mg/ml equivalents.
Confirm PCT completion with bloodwork, not calendar weeks alone.

What Cut Mix 300 Is — And Why Injection-Site Management Defines the Protocol

Cut Mix 300 is a high-concentration, three-compound injectable formulation containing Testosterone Propionate 100mg/ml, Trenbolone Acetate 100mg/ml, and Drostanolone Propionate 100mg/ml, totalling 300mg of active steroid per millilitre — a concentration level that reduces per-injection volume to half of what a standard 150mg/ml blend requires, while simultaneously raising the site-specific irritation load that each injection deposits. Military Pharma designs Cut Mix 300 with PIP-aware athletes in mind: users who understand that short-ester compounds (propionate and acetate carbon chains) generate more localised post-injection discomfort than long-ester alternatives because rapid ester hydrolysis at the injection depot triggers a faster inflammatory micro-response. Compared to a 150mg/ml tri-ester blend delivering the same weekly dose, a 300mg/ml protocol deposits the identical total ester mass in approximately half the fluid volume — a mechanical advantage for injection comfort that is offset by higher per-site active-compound concentration.

PIP Mechanisms at 300mg/ml — Short Esters and Concentration Effects

Post-injection pain at 300mg/ml arises from two compounding factors. First, concentration itself matters: a higher mg/ml solution creates a steeper osmotic and chemical gradient at the intramuscular depot, increasing the local inflammatory signal. Second, propionate and acetate esters hydrolyse within 24–72 hours (confirmed by standard pharmacokinetic ester hydrolysis modelling), releasing free steroid and by-products rapidly rather than across weeks — a process that elevates localised discomfort frequency compared with decanoate- or enanthate-class esters. Trenbolone Acetate additionally carries a well-documented risk of transient cough reflex ('tren cough') on injection, attributed to lymphatic or venous microparticle uptake; aspiration technique and slow injection speed meaningfully reduce incidence. Military Pharma's tactically optimised carrier formulation for Cut Mix 300 targets solvent balance to reduce crystallisation risk at room temperature, a secondary PIP contributor at high-concentration oil solutions.

Injection-Site Rotation Strategy and PCT Timing

Injection-site rotation is not optional at 300mg/ml — it is a pharmacological necessity. Each site requires a minimum 7-day rest period between injections when running daily or every-other-day propionate/acetate protocols; rotating across at least four distinct sites (bilateral glutes, bilateral quads, or deltoids) distributes the inflammatory burden and prevents cumulative fibrosis. Because all three esters in Cut Mix 300 are short-chain, PCT can begin approximately 3–5 days after the final injection — confirmed by de-esterification clearance timelines for propionate and acetate fractions — allowing a faster transition to post-cycle recovery than long-ester blends permit. The 10ml multi-dose vial provides 3,000mg total actives; at a representative 1ml every-other-day protocol, one vial supports approximately 20 injection days of a structured cutting phase.

Usage

WARM THE VIAL: Submerge the sealed vial in a bowl of warm water (38–40°C) for 3 minutes before drawing. This reduces oil viscosity at 300mg/ml, easing aspiration and reducing injection pressure — a primary mechanical contributor to PIP.
SELECT THE INJECTION SITE: Choose from your rotation schedule — bilateral glutes (ventroglute or dorsoglute), bilateral quads (vastus lateralis), or deltoids. Log each site used with date to enforce the 7-day minimum rest interval between same-site injections.
PREPARE THE SYRINGE: Draw the measured volume (0.5–1ml per the dosage phase) using an 18–21 gauge needle for drawing, then switch to a 23–25 gauge, 1–1.5 inch needle for injection into larger muscle groups (25 gauge for deltoids).
ASPIRATE AND INJECT SLOWLY: After needle placement, aspirate briefly to confirm no vascular puncture, then depress the plunger at a controlled rate (approximately 30 seconds per ml). Slow injection reduces depot pressure and lowers tren-cough risk.
POST-INJECTION SITE CARE: Apply gentle pressure with a sterile swab and massage the site lightly for 30–60 seconds to promote oil dispersion through the muscle tissue — dispersed depot volume produces less concentrated local irritation than a tight bolus.
LOG AND ROTATE: Record the site, volume, and any PIP response (scale 1–5) immediately after injection. This log drives informed rotation decisions and identifies whether any specific site consistently produces higher PIP, potentially indicating technique or site-selection refinement is needed.

Warnings

contraindications: Contraindicated in individuals with prostate cancer, breast cancer, or hypercalcaemia regardless of compound selection.

Not suitable for female athletes due to the androgenic potency of all three active compounds, particularly Trenbolone Acetate.

Cardiovascular disease, uncontrolled hypertension, or left ventricular hypertrophy are absolute contraindications.

Do not use if allergic to any component of the formulation including carrier oil or solvent excipients.

side_effects: Trenbolone Acetate is associated with transient cough reflex ('tren cough') immediately post-injection in a subset of users; slow injection technique reduces incidence.

Androgenic effects include acne, accelerated scalp hair thinning in genetically predisposed individuals, and increased sebum production.

Cardiovascular effects: haematocrit elevation, LDL increase, HDL suppression — require lipid monitoring throughout the cycle.

Neurological: vivid dreams and sleep disruption are common with Trenbolone Acetate; night sweats may occur.

Repeated injection at the same site without adequate rotation may lead to subcutaneous nodule formation or localised fibrosis over time.

monitoring: Full blood count and lipid panel before cycle commencement and at mid-cycle (week 4–5) minimum.

Blood pressure monitoring twice weekly throughout the cycle — high-concentration trenbolone accelerates haematocrit rise.

Liver enzyme panel (ALT/AST) at cycle start and end; injectable blends carry lower hepatic burden than oral compounds but monitoring remains standard practice.

Prolactin and oestradiol levels should be checked mid-cycle given Trenbolone's progestogenic activity and Testosterone Propionate's aromatisation potential.

pct: PCT begins approximately 3–5 days after the final injection of Cut Mix 300, utilising propionate and acetate ester clearance timelines.

A SERM-based protocol (Nolvadex 40/40/20/20mg or Clomid 50/50/25/25mg over 4 weeks) is the standard approach; individual suppression depth determines whether 4 or 6 weeks is appropriate.

Bloodwork at the end of PCT week 4 confirms whether hormonal recovery is on track or whether the protocol requires extension.

A dopamine agonist (Cabergoline) may be warranted if prolactin elevation is confirmed via blood panel during or after the cycle.

Frequently asked questions

How many weeks should a full PCT run after a Cut Mix 300 cycle using short esters?: A standard post-cycle therapy following a short-ester blend like Cut Mix 300 typically runs 4–6 weeks. Because propionate and acetate esters clear within 3–5 days of the last injection, hormonal recovery can begin earlier than with long-ester cycles. Most protocols use a SERM (Nolvadex or Clomid) for 4 weeks minimum, extending to 6 weeks if suppression was deep or cycle duration exceeded 10 weeks.
Can running PCT for too long after a tri-ester cutting cycle cause any harm?: Prolonged SERM use beyond 6–8 weeks can itself disrupt oestrogen signalling, potentially affecting lipid profiles and joint lubrication. There is no therapeutic benefit to extending SERM administration once bloodwork confirms LH, FSH, and testosterone have normalised. Monitoring via blood panels at weeks 4 and 6 of PCT is the standard method for determining when to stop rather than defaulting to a fixed extended duration.
When can PCT be shortened after Cut Mix 300, and what conditions allow it?: PCT can potentially be shortened to 3–4 weeks when cycle duration was brief (6–8 weeks), suppression was moderate rather than severe, and blood panels at the end of week 3 already show LH and testosterone returning toward baseline. Short-ester clearance via propionate and acetate de-esterification means recovery hormones are unobstructed earlier, but bloodwork confirmation — not assumptions — should determine when PCT can be concluded.
Can Cut Mix 300 be drawn into an insulin syringe for small-dose injections?: Insulin syringes (0.5ml or 1ml, 27–29 gauge) can technically draw Cut Mix 300, but the 300mg/ml concentration means even a 0.25ml draw delivers 75mg of combined actives — making micro-precision essential. The narrow gauge slows draw time with viscous oil; warming the vial to body temperature (38–40°C) in a warm-water bath for 2–3 minutes reduces viscosity and eases insulin-syringe loading without degrading the active compounds.
How should the Cut Mix 300 10ml vial be stored after first use?: After the rubber stopper is first punctured, store the vial in a cool, dark environment between 15–25°C — room temperature is acceptable for multi-dose vials sealed with chlorobutyl stoppers. Refrigeration (2–8°C) extends shelf life but may cause the oil solution to thicken; allow the vial to return to room temperature before drawing. Avoid repeated temperature cycling. Discard any vial showing visible particulate matter, cloudiness, or colour change regardless of remaining volume. (2) angle_used

Manufacturer

Military Pharma's distribution and logistics framework for Cut Mix 300 addresses a practical challenge that is specific to high-concentration, short-ester injectable blends: the requirement for cold-chain integrity during transit without exposing the oil-based formulation to temperature extremes that can compromise carrier-oil homogeneity or active-compound suspension stability. Distribution partners operating under Military Pharma's supply agreements are required to maintain documented temperature logs across the transit window — a requirement that becomes operationally significant for a 300mg/ml formulation, where any carrier-oil separation event during shipping would manifest as visible phase inconsistency that the end user could detect on visual inspection. Vial labelling for Cut Mix 300 carries a lot-number reference that links to Military Pharma's internal batch documentation, including the fill date and analytical release data, giving distribution-chain participants — wholesaler, retailer, and end user — a traceable connection to the production event. This lot-level traceability is particularly relevant for a multi-compound, high-concentration vial because it allows any distribution-stage quality query to be referred back to the specific batch file rather than resolved by product-level generalisation.

Product details

Brand	Military Pharma
Active ingredient	mix product
Also known as	Steroid-Mix, Mehrkomponenten-Mischung, Cut Mix, Gain Mix, Cut Mix 300, Military Pharma Steroid-Mix
Strength	300 mg
Form	Vial
Pack size	1 piece
Item number	INJ-MIX-MIL-300-007

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Mixobolin-200 200mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Hardcore Cutting

Mixobolin-200 200mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Mixobolin-200 by BM Pharmaceuticals combines Trenbolone Acetate 50mg, Drostanolone Propionate 50mg, and Testosterone Propionate 100mg per millilitre — 200mg/ml total — across 10 individually sealed single-dose glass ampoules, formulated to distribute androgen receptor occupancy across three mechanistically distinct compound classes rather than concentrating binding pressure through a single high-affinity pathway. All three propionate and acetate esters clear within 2–3 days, allowing cycle termination to be executed precisely when training output signals diminishing receptor responsiveness, with post-cycle therapy starting as early as 3–5 days after the final ampoule. Per-compound HPLC quantification and LAL endotoxin screening are applied at batch level; each ampoule is hermetically sealed under nitrogen-blanketed aseptic fill conditions before carton assembly.

€76.00

Recomp Optimizer

Mix Products Injection 250mg/ml 10ml Vial by Genesis

Genesis Mix Products Injection is a 250mg/ml tri-ester hybrid injectable combining Trenbolone Acetate 40mg, Nandrolone Decanoate 90mg, and Testosterone Mix 120mg per ml, formulated specifically to support precise microdosing protocols in a 10ml multi-dose vial. The dual 19-nor structure combined with a testosterone base makes post-cycle therapy exceptionally demanding — users must expect an aggressive, extended SERM regimen beginning approximately 14–21 days after the final injection, timed to the decanoate ester's clearance. Vial integrity, concentration accuracy, and sterility are verified through reversed-phase HPLC quantification and LAL endotoxin testing; every released batch carries a traceable certificate of analysis.

€54.00

Mass Building

NTD 400 400mg/ml 10ml Vial by GenTec

GenTec NTD 400 is a 400mg/ml tri-ester injectable blend — Nandrolone Decanoate 100mg, Drostanolone Enanthate 100mg, Testosterone Enanthate 200mg — formulated specifically for cruise & blast mass-building protocols in a 10ml multi-dose vial. Each millilitre delivers 4,000mg of total active ingredient across the full vial, with long-acting esters sustaining stable plasma levels throughout extended blast phases without the need for daily injections. Quality assurance is enforced through HPLC concentration verification, LAL endotoxin testing, and GMP-compliant aseptic fill-and-finish; batch certificates are available per lot.

€50.00

Best Value

Cut Stack 150 150mg/ml 10ml Vial by Hilma Biocare

Cut Stack 150 by Hilma Biocare is a 150mg/ml injectable cutting blend — Testosterone Propionate 50mg/ml, Trenbolone Acetate 50mg/ml, and Drostanolone Propionate 50mg/ml — supplied in a 10ml multi-dose vial and formulated exclusively for advanced cutting protocols, with an absolute contraindication against TRT or anti-aging use. Because all three compounds carry a 2–3 day half-life, plasma levels fall to sub-suppressive thresholds within days of the final injection, opening the post-cycle recovery window approximately 3–5 days after the last dose — a materially earlier point than long-ester injectable cycles, and driven by ester hydrolysis rather than the hepatic clearance kinetics that govern oral-cycle PCT scheduling. Every production lot is released under Hilma Biocare's analytical framework: HPLC potency confirmation and LAL endotoxin testing applied batch-by-batch, with certificates accessible via the brand's verification portal.

€54.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00